Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11).

Next Previous
Trial Profile

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Heart transplant rejection
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Nov 2012 Actual initiation date changed from Feb 2011 to Sep 2011 as reported by ClinicalTrials.gov.
    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top